Get started
Author

Anna Säll

ORCID: 0000-0001-5287-2984
Observed ORCID: 0000-0001-5287-2984
OpenAlex ID: A5003121489
Generation and analyses of human synthetic antibody libraries and their application for protein microarrays
2016 · Anna Säll, Maria Walle, et al. · Protein Engineering Design and Selection · 41
Bispecific antibodies targeting CD40 and tumor-associated antigens promote cross-priming of T cells resulting in an antitumor response superior to monospecific antibodies
2022 · Karin Hägerbrand, Laura Varas, et al. · Journal for ImmunoTherapy of Cancer · 34
PDF
A Multicenter Trial Defining a Serum Protein Signature Associated with Pancreatic Ductal Adenocarcinoma
2015 · Anna S. Gerdtsson, Núria Malats, et al. · International Journal of Proteomics · 30
PDF
Combination of phage and Gram-positive bacterial display of human antibody repertoires enables isolation of functional high affinity binders
2017 · Francis Jingxin Hu, Anna-Luisa Volk, et al. · New Biotechnology · 22
PDF
The Bispecific Tumor Antigen-Conditional 4–1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
2022 · Michelle H. Nelson, Sara Fritzell, et al. · Molecular Cancer Therapeutics · 12
ATOR-1017 (evunzekibart), an Fc-gamma receptor conditional 4-1BB agonist designed for optimal safety and efficacy, activates exhausted T cells in combination with anti-PD-1
2023 · Karin Enell Smith, Sara Fritzell, et al. · Cancer Immunology Immunotherapy · 10
PDF
RUBY® – a tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties
2024 · Barnabas Nyesiga, Mattias Levin, et al. · mAbs · 9
PDF
Advancing the immunoaffinity platform AFFIRM to targeted measurements of proteins in serum in the pg/ml range
2018 · Anna Säll, Daniel Corbee, et al. · PLoS ONE · 8
PDF
AFFIRM—A Multiplexed Immunoaffinity Platform That Combines Recombinant Antibody Fragments and LC-SRM Analysis
2014 · Anna Säll, Fredrika Carlsson, et al. · Journal of Proteome Research · 7
Development of Phage-Based Antibody Fragment Reagents for Affinity Enrichment of Bacterial Immunoglobulin G Binding Proteins
2015 · Anna Säll, Kristoffer Sjöholm, et al. · Journal of Proteome Research · 6
858 A bispecific antibody targeting CD40 and EpCAM induces superior anti-tumor effects compared to the combination of the monospecific antibodies
2020 · Peter Ellmark, Karin Hägerbrand, et al. · Journal for ImmunoTherapy of Cancer · 5
751 Neo-X-Prime bispecific antibodies targeting CD40 and tumor antigens promote cross-presentation of tumor exosome-derived neoantigen and induce superior anti-tumor responses compared to CD40 mAb
2021 · Karin Hagerbrand, Mattias Levin, et al. · Journal for ImmunoTherapy of Cancer · 2
PDF
ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al. · Cancer Immunology Research · 1
PDF
Activation of the CD137 Pathway in T cells by a CD137 × 5T4 bispecific ADAPTIR Molecule Requires Co-engagement of CD137 and 5T4
2018 · Gabriele R Blahnik-Fagan, Robert Bader, et al. · The Journal of Immunology · 1
Advancing the global proteome survey platform by using an oriented single chain antibody fragment immobilization approach
2015 · Anna Säll, Helena Persson, et al. · New Biotechnology · 1
PDF
Data from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Figure S1 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Figure S17 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Figure S15 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Table S2 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Figure S7 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Figure S19 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Figure S21 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Figure S8 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Supplementary Figure S16 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade
2025 · Hampus Andersson, Ida Uddbäck, et al.
Works count: 47
Citation count: 189
H-index: 8
I10-index: 6
Year
Topic
Type